Investigating the role of a key enzyme in cancer development
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer
This study is looking at how a missing enzyme called MTAP affects cancer growth and whether cancer cells without it might respond better to certain treatments, with the goal of finding new ways to help treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10840890 on NIH RePORTER |
What this research studies
This research focuses on understanding how the enzyme methylthioadenosine phosphorylase (MTAP) influences cancer progression. It examines the effects of MTAP loss, which is common in various cancers, and how this loss leads to the accumulation of a compound called 5'-deoxy-5'-methylthioadenosine (MTA). The study aims to uncover the mechanisms by which MTA affects tumor growth and the potential sensitivity of MTAP-deleted cancer cells to specific treatments. By exploring these pathways, the research seeks to identify new therapeutic targets for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit MTAP deletion, including both solid tumors and hematologic malignancies.
Not a fit: Patients whose cancers do not involve MTAP deletion or those with non-malignant conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for cancers associated with MTAP loss.
How similar studies have performed: Previous research has shown promising results in understanding the role of MTAP in cancer, indicating that this approach has potential for significant findings.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kruger, Warren D — Research Inst of Fox Chase Can Ctr
- Study coordinator: Kruger, Warren D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.